Evidence map›Paper›PMID 31166946›Full record

ArticlePLoS neglected tropical diseases2019

Peripheral immune response in the African green monkey model following Nipah-Malaysia virus exposure by intermediate-size particle aerosol.

Abigail Lara, Yu Cong, Peter B Jahrling, Mark Mednikov, Elena Postnikova, Shuiqing Yu, Vincent Munster, Michael R Holbrook

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Nipah virus: pathogenesis, genome, diagnosis, and treatment.Applied microbiology and biotechnology · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. AnFrontiers in chemical biology · 2024
    Article
  11. Review
  12. Article
  13. Review
  14. The Immunobiology of Nipah Virus.Microorganisms · 2022
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abigail LaraNIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States of America.
Yu CongNIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States of America.
Peter B JahrlingNIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States of America.
Mark MednikovNIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States of America.
Elena PostnikovaNIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States of America.
Shuiqing YuNIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States of America.
Vincent MunsterVirus Ecology Unit, Laboratory of Virology, Rocky Mountain Laboratories, Hamilton, MT, United States of America.
Michael R HolbrookNIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States of America.ORCID 0000-0002-0824-2667

Funding

Virus Ecology UnitZIAAI001179 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MUNSTER, VINCENT · 2013 to 2025
$24.3M
NIAID NIH HHS HHSN272200700016I
6 · The paper itself

Abstract

The ability to appropriately mimic human disease is critical for using animal models as a tool for understanding virus pathogenesis. In the case of Nipah virus (NiV), infection of humans appears to occur either through inhalation, contact with or consumption of infected material. In two of these circumstances, respiratory or sinusoidal exposure represents a likely route of infection. In this study, intermediate-size aerosol particles (~7 μm) of NiV-Malaysia were used to mimic potential routes of exposure by focusing viral deposition in the upper respiratory tract. Our previous report showed this route of exposure extended the disease course and a single animal survived the infection. Here, analysis of the peripheral immune response found minimal evidence of systemic inflammation and depletion of B cells during acute disease. However, the animal that survived infection developed an early IgM response with rapid development of neutralizing antibodies that likely afforded protection. The increase in NiV-specific antibodies correlated with an expansion of the B cell population in the survivor. Cell-mediated immunity was not clearly apparent in animals that succumbed during the acute phase of disease. However, CD4+ and CD8+ effector memory cells increased in the survivor with correlating increases in cytokines and chemokines associated with cell-mediated immunity. Interestingly, kinetic changes of the CD4+ and CD8bright T cell populations over the course of acute disease were opposite from animals that succumbed to infection. In addition, increases in NK cells and basophils during convalescence of the surviving animal were also evident, with viral antigen found in NK cells. These data suggest that a systemic inflammatory response and "cytokine storm" are not major contributors to NiV-Malaysia pathogenesis in the AGM model using this exposure route. Further, these data demonstrate that regulation of cell-mediated immunity, in addition to rapid production of NiV specific antibodies, may be critical for surviving NiV infection.

Indexed as

AerosolsImmunity, HumoralInhalation ExposureAnimalsAntibodies, NeutralizingAntibodies, ViralB-LymphocytesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesChlorocebus aethiopsCytokinesDisease Models, AnimalFemaleHenipavirus InfectionsHumansImmunity, CellularAerosolsAntibodies, NeutralizingAntibodies, ViralCytokinesImmunoglobulin M

Identifiers

PMID31166946
PMCPMC6576798
OpenAlexW2948136289

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.